Choose Your Country or Region

Pramipexole

Name: Pramipexole
Brand: Selleck Chemicals
SKU: S2460
Rating: 5 (2 reviews)

Synonyms: SND 919,Mirapexin,Sifrol,Mirapex

Catalog No.S2460 Purity: 99.98%

Pramipexole (SND 919,Mirapexin,Sifrol,Mirapex) is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively.

Pramipexole Chemical Structure

CAS: 104632-26-0

Selleck's Pramipexole has been cited by 2 publications

Purity & Quality Control

Batch: Purity: 99.98%

99.98

Pramipexole Related Products

Related Targets	D1 receptor D2 receptor D3 receptor D5 receptor DAT D4 receptor	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Neuronal Signaling Compound Library CNS-Penetrant Compound Library Anti-alzheimer Disease Compound Library	Click to Expand

Signaling Pathway

Dopamine Receptor Signaling Pathway

Choose Selective Dopamine Receptor Inhibitors

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
CHO cells	Function assay				High inhibition constant against [3H]spiperone binding to human Dopamine receptor D3 expressed in CHO cells, Ki=0.88 nM	15801839
Click to View More Cell Line Experimental Data

Biological Activity

Description

Pramipexole (SND 919,Mirapexin,Sifrol,Mirapex) is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively.

Targets

D3 receptor ^[1]	D2L Receptor ^[1]	D2S Receptor ^[1]	D4 receptor ^[1]
0.5 nM(Ki)	2.2 nM(Ki)	3.9 nM(Ki)	5.1 nM(Ki)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT03683225	Active not recruiting	Idiopathic Parkinson Disease	Chase Therapeutics Corporation	April 1 2019	Phase 2
NCT03642964	Active not recruiting	Major Depressive Disorder (MDD)	Chase Therapeutics Corporation	September 10 2018	Phase 2
NCT02101138	Unknown status	Hypereosinophilic Syndrome	National Institute of Allergy and Infectious Diseases (NIAID)\|Knopp Biosciences\|National Institutes of Health Clinical Center (CC)	March 14 2014	Phase 2
NCT01733199	Completed	Parkinson''s Disease\|Secondary Behavioural Addiction	Nantes University Hospital	October 2012	Phase 4
NCT01607034	Completed	Healthy Volunteers	Knopp Biosciences	June 2012	Phase 1
NCT01597310	Completed	Healthy Volunteers	Knopp Biosciences	May 2012	Phase 1

References

[1] Kvernmo T, et al. Clin Ther, 2006, 28(8):1065-78.

Chemical Information & Solubility

Molecular Weight	211.33	Formula	C₁₀H₁₇N₃S
CAS No.	104632-26-0	SDF	Download Pramipexole SDF
Smiles	CCCNC1CCC2=C(C1)SC(=N2)N
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 42 mg/mL ( (198.74 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 42 mg/mL

Water : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):